MDB Capital (MDBH) versus Its Peers Critical Comparison

Risk & Volatility

MDB Capital has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, MDB Capital’s rivals have a beta of 5.21, suggesting that their average share price is 421% more volatile than the S&P 500.

Earnings and Valuation

This table compares MDB Capital and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MDB Capital	$5.99 million	-$6.97 million	-2.56
MDB Capital Competitors	$2.91 billion	$383.60 million	21.83

MDB Capital’s rivals have higher revenue and earnings than MDB Capital. MDB Capital is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

0.4% of MDB Capital shares are owned by institutional investors. Comparatively, 34.3% of shares of all “Nondepository credit institutions” companies are owned by institutional investors. 55.5% of MDB Capital shares are owned by company insiders. Comparatively, 22.6% of shares of all “Nondepository credit institutions” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares MDB Capital and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDB Capital	N/A	-56.19%	-48.57%
MDB Capital Competitors	-62.34%	-73.50%	-4.01%

Summary

MDB Capital rivals beat MDB Capital on 6 of the 9 factors compared.

MDB Capital Company Profile

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business. The company was founded in 1997 and is based in Addison, Texas.